The Effects of Inhaled Iloprost on Congenital Heart Disease With Eisenmenger Syndrome

Identification of the pathophysiology associated with Eisenmenger's syndrome has led to the evaluation of targeted therapies. Iloprost, a prostacyclin analogue, is one such targeted therapy used in patients with Eisenmenger's syndrome. The purpose of our study is to assess the effects of inhaled iloprost on patients with Eisenmenger's syndrome.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Eisenmenger's Syndrome Cardiovascular Abnormalities Cardiovascular Diseases Congenital Abnormalities Congenital, Hereditary, and Neonatal Diseases and Abnormalities Eisenmenger Complex Heart Defects, Congenital Heart Diseases

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

patients with Eisenmenger's syndrome diagnosed by right side cardiac catheterization

Exclusion criteria

Sponsors and collaborators

Lead sponsor

Gachon University Gil Medical Center

Other

Registry information

Official study title

Study of the Effects of Inhaled Iloprost on Congenital Heart Disease With Eisenmenger Syndrome

Important dates

Study start: 2007
Study completion: 2010
First posted: Jan 26, 2011
Registry last updated: Jan 26, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed